Navigation Links
Depression Study Published on BCM-95 Curcumin
Date:7/11/2013

DALLAS, July 11, 2013 /PRNewswire/ -- A recently published clinical trial on major depressive disorder (MDD) showed that high absorption BCM-95® Curcumin equaled the effects of the prescription drug fluoxetine (generic form of Prozac®), without the adverse effects. [J Sanmukhani, V Satodia, J Trived, T Patel, D Tiwar, B Panchal, A Goel and CB Tripathi. Efficacy and safety of curcumin in major depressive disorder: A randomized controlled trial. Phytotherapy Research.] BCM-95 Curcumin is absorbed 7 to 10 times better than plain curcumin and has been the subject of 13 published studies, 8 of them human clinical trials.

When asked how curcumin is applicable to depression, Dr. Ajay Goel, Baylor Research Institute and Charles A Sammons Cancer Center, Baylor University Medical Center and study co-author, stated, "It is a novel and surprising application for this natural medicine. People with depression have higher levels of inflammation in the brain. Also, people with depression have lower levels of neurogenesis in the brain, meaning they make fewer new brain cells than people with no history of depression. Curcumin is both a potent anti-inflammatory agent and a powerful stimulator for neurogenesis. A recent animal study was published on BCM-95 Curcumin compared to both fluoxetine and imipramine (an older class of antidepressant medications) and showed excellent results. We are excited to learn the effectiveness of BCM-95 Curcumin in a human study." 

When asked about the importance of this study, Dr. Goel replied, "Depression is a major global public health issue leading to substantial disability. The pharmaceutical interventions can be quite costly, and have many potentially serious adverse effects. There are also many people whose disease does not fully respond to treatment. The BCM-95 Curcumin used in this study shows efficacy on major depressi
'/>"/>

SOURCE Ajay Goel, Ph.D.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Results Reported for Phase Ib Open-Label Clinical Trial for the Treatment of Depression Using External Trigeminal Nerve Stimulation (eTNS™) - The USB Port to the Brain™
2. Joint Commission Issues Sentinel Event Alert on Opioid-Induced Respiratory Depression
3. New Inspirational Memoir Aims to Support Individuals Battling Depression
4. Physician-Patient Alliance for Health & Safety: Addressing The Joint Commission Opioid Warnings Can Reduce Respiratory Depression and Improve Patient Safety in Hospitals
5. Can Omega-3 Fish Oil Ward Off Post-Partum Depression
6. Braincells, Inc. Announces the Successful Completion of a Multiple Ascending Dose Study of BCI-838, a Group II mGluR2/3 Antagonist, and the Companys Plans for a Proof-of-Concept Study in Patients with Treatment-Resistant Depression
7. NeuroSigma Invited to Present an Overview of eTNS for the Treatment of Epilepsy and Depression at The Royal Society of Medicine in London
8. US B12 Shots Discusses B12 Deficiency Link to Depression
9. Vitamin B12 Deficiency Linked to Depression says New Article by US HCG Injections
10. A Greater Effect on Depressive Symptoms than Current Treatments is One of the Greatest Unmet Needs in Treatment-Resistant Depression
11. National 2020 Mom Project Campaign Launches to Address Postpartum Depression by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Kan. , July 24, 2014  Parnell ... two compounds that will be added to Parnell,s ... Australian-based CIMTECH Pty Ltd, a biotechnology company. The ... 122 have shown promise in bone regeneration and ... to develop the compounds for the veterinary market ...
(Date:7/24/2014)... MARSEILLE , Frankreich, July 24, ... , Weltweite Exklusivlizenz der Universität ... von Tests auf SF3B1-Mutationen, einschließlich von Next-Generation-Sequencing ... Test weist Mutationen des SF3B1-Gens nach, die ... günstigen Krankheitsverlauf vermuten lassen  QIAGEN ...
(Date:7/24/2014)... -- Abaxis, Inc. (NasdaqGS: ABAX ), a medical ... financial results for the first fiscal quarter ended June ... Revenues of $47.5 million, up 10% over last year,s ... 50% over last year,s comparable quarter. Revenues ... up 20% over last year,s comparable quarter. , ...
Breaking Medicine Technology:Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 2Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 3Parnell Acquires License for Intellectual Property and Rights to Develop Compounds for Bone and Dermal Regeneration 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Pieris AG presented the results ... most advanced Anticalin ® , PRS-050, an anti-VEGF ... Conference held in San Francisco, California.  The dose-escalation ... tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of PRS-050 ...
... /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord ... operator of the largest network of radiotherapy and diagnostic imaging ... for the third quarter ended September 30, 2011. ... revenues were RMB124.7 million ($19.6 million)(A) in the third quarter ...
Cached Medicine Technology:Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 2Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference 3Concord Medical Reports Third Quarter 2011 Financial Results 2Concord Medical Reports Third Quarter 2011 Financial Results 3Concord Medical Reports Third Quarter 2011 Financial Results 4Concord Medical Reports Third Quarter 2011 Financial Results 5Concord Medical Reports Third Quarter 2011 Financial Results 6Concord Medical Reports Third Quarter 2011 Financial Results 7Concord Medical Reports Third Quarter 2011 Financial Results 8Concord Medical Reports Third Quarter 2011 Financial Results 9Concord Medical Reports Third Quarter 2011 Financial Results 10Concord Medical Reports Third Quarter 2011 Financial Results 11Concord Medical Reports Third Quarter 2011 Financial Results 12Concord Medical Reports Third Quarter 2011 Financial Results 13Concord Medical Reports Third Quarter 2011 Financial Results 14Concord Medical Reports Third Quarter 2011 Financial Results 15
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... dismissal and summary judgment in two DePuy Pinnacle hip ... paving the way for the claims to go before ... reports. In an opinion rendered on July 18th, U.S. ... Texas, ruled that the two Plaintiffs’ claims may proceed ...
(Date:7/25/2014)... As reported by the New Orleans Advocate in ... (7/3), the state of Louisiana has recently seen a large ... cocaine. Officials believe the increase is due to a misconception ... marijuana. However, both doctors and police confirm that that belief ... call it “poison,” doctors have acknowledged that the Louisiana Poison ...
(Date:7/25/2014)... Youngstown, Ohio (PRWEB) July 25, 2014 ... processed foods? How to know? , Read the labels! ... labels and determine how it relates to health during ... 12:30 p.m. Aug. 1 at Humility House, 755 Ohltown ... Lackey will lead an informational discussion and answer questions. ...
(Date:7/25/2014)... of America (GSA) the nation,s largest ... has chosen Heather M. Young, PhD, RN, ... the 2014 recipient of the Doris Schwartz Gerontological ... by GSA,s Health Sciences Section, is given to ... outstanding and sustained contribution to gerontological nursing research. ...
(Date:7/25/2014)... As reported by Wood TV 8 in the article ... a nearly 500-person increase in heroin related overdose deaths in ... 1999 and 2002, the toll increased to 728 during the ... drug users in Michigan have turned to heroin after getting ... price of both substances, noting that an 80-milligram pill can ...
Breaking Medicine News(10 mins):Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 2Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 3Health News:First Federal DePuy Pinnacle Hip Lawsuits Headed for Trial, As Judge Denies Defense Motions For Dismissal, Summary Judgment, Bernstein Liebhard LLP Reports 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Learn to Decipher Food Labels at Humility House 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2Health News:Rise in Heroin Use, Overdose Deaths in Michigan 2
... decision to lower requirements for designation , , WEDNESDAY, ... U.S. government decision to lower the benchmark for ... new Johns Hopkins Medical Institutions study reports the ... 14 transplants a year. , The Centers for ...
... A new study from the Monell Center increases ... nausea and vomiting that often afflict patients undergoing ... of new approaches to combat these debilitating side ... the nausea and vomiting that accompany chemotherapy treatment, ...
... (Nasdaq: AMCS ),a leader in radiology and medical image and ... investors at the UBS Global Healthcare Services Conference in New,York., ... -- Tuesday, February 12, 2008 ... 11:30 a.m. (Eastern Time), ...
... Idaho, January 30, 2008 Preventative heart healthcare gains ... NHWK), announced its involvement as the exclusive radiology provider ... Initiative is a joint research effort to advance the ... to be the primary underlying cause of heart attacks ...
... Thanks to Nutrition on the Go, an,innovative new program ... more than 1,700 restaurants nationwide is available in,a flash through ... and menu item., Not cell phone savvy? No worries. ... menu item you need help with, then send that info ...
... Jan. 30 Onmark, a leading,national group ... McKesson Specialty company, today announced the launch ... goal of helping community-based,oncology practices improve the ... which is facilitated through OTN,s industry-leading Lynx,Mobile(TM) ...
Cached Medicine News:Health News:Study Challenges New Benchmark for High-Volume Heart Transplant Hospitals 2Health News:Explaining chemotherapy-associated nausea 2Health News:AMICAS to Present at UBS Global Healthcare Services Conference 2Health News:NightHawk Radiology exclusive radiology provider for high-risk plaque research initiative 2Health News:Ring Up Instant Nutrition Info via Text Message to DIET1 (34381) 2Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 2Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 3Health News:Onmark Launches Integrated Quality(TM) Program to Help Physicians Succeed With National Quality Initiatives 4